This is an open-label, Phase 1, first-in-human, dose escalation and expansion study designed
to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and tumor response
profile of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6)
antibody BAY1834942 in patients with advanced solid tumors known to have a prevalence for
CEACAM6 expression.
The study consists of dose escalation and a tumor type-specific expansion.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Antibodies Immunoglobulin G Immunoglobulins Pembrolizumab